European regulators could take a harder line on Agios' blood cancer drug

European regulators could take a harder line on Agios' blood cancer drug

STAT Plus: European regulators could take a harder line on the review of an Agios blood cancer drug

By ADAM FEUERSTEIN

RUBY WALLAU FOR STAT

A European regulatory setback for a Bristol-Myers Squibb blood-cancer drug could have a negative spillover effect for Agios Pharmaceuticals.

READ MORE